menu toggle

Five things to watch as the Biosimilars market heats up in 2022

Pharmaphorum, Beth McMahon

As pressure mounts on the U.S. Congress and the White House to curtail prescription drug prices, many experts continue to point to biosimilars and their promising potential to usher in competition, increase access, and drive down costs for patients—and the U.S. market is just beginning to heat up. In the latter half of 2021, there was lots of exciting movement. The Food and Drug Administration (FDA) approved four biosimilars, three of which were industry firsts: leading with Semglee, the first interchangeable biosimilar ever approved; followed by Byooviz, which broke into the ophthalmology/retina space; and then Cyltezo, yet another Humira biosimilar but the first to receive the interchangeable designation. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko. With 34 approved biosimilars and dozens more in the pipeline, what does this year have in store? Here are five things I have my eye on in 2022.

For the full article, please visit Pharmaphorum.